MEDFIELD, MA--(Marketwire - March 04, 2010) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) (www.symbollon.com) is pleased to announce that it has initiated retail sales of iogen™, its patented dietary supplement for improving women's breast health, through its web site, www.buyiogen.com. Iogen is the first dietary supplement formulated to promote breast health for women. As part of the initial launch, iogen will be available for a limited-time introductory price of $19.95 (a 70% discount off the retail price) for a 2-month supply. The offer is backed by a 60-day money back guarantee.
"Our company has hit its first significant milestone," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "We are pleased to make iogen available now to women through our newly designed web site, www.buyiogen.com. Iogen is the first dietary supplement clinically shown to promote breast health. We believe that iogen addresses a significant need for women concerned about improving their breast health. The introductory offer will allow women to try iogen for 2 months without any financial risk. We are so confident that women suffering from breast pain or fibrocystic breast disease will be completely satisfied with the product that we are backing our introductory offer with a no questions money back guarantee. With our most recent announcement of our commercialization advisory board and the talent that has joined Symbollon, we are diligently pursuing additional retail distribution channels for our product. We are committed to making iogen available in as many outlets as possible so every woman who has interest in improving her breast health has easy access to it."
Symbollon Pharmaceuticals, Inc. Resources:
-- Corporate Profile: http://symbollon.com/corporate_profile.htm
-- FAQ: http://symbollon.com/faq.htm
-- Technology Overview: http://symbollon.com/technology_overview.htm
About Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA)
Symbollon is a specialty biotechnology company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.
This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercialize iogen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) we will be able to complete the acquisition of New Zealand Pure under the terms of the letter of intent, (v) Symbollon will be able to commercialize other products and (vi) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.